Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma
2021
Abstrakt
We analyzed children and adolescents with PMBCL confirmed by central histopathological review, excluding mediastinal grey zone lymphoma, enrolled in the B04 trial (German clinical trial registry, DRKS00009436) or the NHL-BFM Registry 2012 between 2004 and 2019 to assess the efficacy of intensified B-NHL-BFM chemotherapy (n=29 patients) and modified DA-EPOCH-R (n=67 patients), compare it retrospectively to the treatment regimen in the NHL-BFM 95 trial (N95, n=20 patients) and to identify risk factors for treatment failure with DA-EPOCH-R.